Alnylam Pharmaceuticals
ALNY
NZ$529.30
Share price
-2.05%
Change (1 day)
27.13%
Change (1 year)
Categories
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Alnylam Pharmaceuticals (ALNY) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : NZ$6.83 Billion
According to Alnylam Pharmaceuticals 's latest financial reports the company's total liabilities are NZ$6.83 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Alnylam Pharmaceuticals - Total liabilities on balance sheet (from 2003 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | NZ$7.39 B | 15.52% |
| 2023-12-31 | NZ$6.40 B | 9.77% |
| 2022-12-31 | NZ$5.83 B | 30.45% |
| 2021-12-31 | NZ$4.47 B | 34.99% |
| 2020-12-31 | NZ$3.31 B | 133.32% |
| 2019-12-31 | NZ$1.42 B | 249.15% |
| 2018-12-31 | NZ$0.40 B | 26.53% |
| 2017-12-31 | NZ$0.32 B | -35% |
| 2016-12-31 | NZ$0.49 B | 177.92% |
| 2015-12-31 | NZ$0.17 B | -2.72% |
| 2014-12-31 | NZ$0.18 B | 0.09% |
| 2013-12-31 | NZ$0.18 B | -2.04% |
| 2012-12-31 | NZ$0.18 B | -11.18% |
| 2011-12-31 | NZ$0.21 B | -31.06% |
| 2010-12-31 | NZ$0.30 B | -27.07% |
| 2009-12-31 | NZ$0.41 B | -31.24% |
| 2008-12-31 | NZ$0.60 B | 57.95% |
| 2007-12-31 | NZ$0.38 B | 597.81% |
| 2006-12-31 | NZ$55.11 M | 3.02% |
| 2005-12-31 | NZ$53.5 M | 91.22% |
| 2004-12-31 | NZ$27.97 M | -70.61% |
| 2003-12-31 | NZ$95.2 M | 140.05% |
| 2002-12-31 | NZ$39.66 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Arrowhead Pharmaceuticals
ARWR | NZ$1.48 B | -78.30% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | NZ$13.59 B | 99.04% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | NZ$3.87 B | -43.33% | 🇺🇸 USA |
 OPKO Health
OPK | NZ$1.36 B | -80.07% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | NZ$9.66 M | -99.86% | 🇺🇸 USA |
 Novartis NVS | NZ$102.50 B | 1,400.32% | 🇨🇭 Switzerland |
 Sanofi SNY | NZ$103.66 B | 1,417.19% | 🇫🇷 France |
 Teva Pharmaceutical Industries TEVA | NZ$53.59 B | 684.36% | 🇮🇱 Israel |